Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Maffrand

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Biochemical Pharmacology|December 15, 1990
The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1C Gachet, J P Cazenave, P Ohlmann, et al.
Fundamental & Clinical Pharmacology|January 1, 1995
Neuropharmacological profile of non-peptide neurotensin antagonistsD Gully, F Jeanjean, M Poncelet, et al.
Life Sciences|January 1, 1996
Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensinD Gully, L Lespy, M Canton, et al.
Kidney International|August 1, 1996
Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059C Serradeil-Le Gal, D Raufaste, E Marty, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 29, 2001
Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidusB Pouzet, C Serradeil-Le Gal, N Bouby, et al.
Biochemical and Biophysical Research Communications|October 23, 1997
Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cellsS Ferry, B Chatel, R H Dodd, et al.
Biochemical and Biophysical Research Communications|February 28, 1994
Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranesC Serradeil-Le Gal, D Raufaste, E Marty, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatmentB Bourrié, E Bribes, M Esclangon, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 29, 2000
Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertensionF Lacheretz, A Barbier, C Serradeil-Le Gal, et al.
Thrombosis and Haemostasis|August 1, 1994
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1AP Savi, J Combalbert, C Gaich, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Biochemical Pharmacology|December 15, 1990
The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1C Gachet, J P Cazenave, P Ohlmann, et al.
Fundamental & Clinical Pharmacology|January 1, 1995
Neuropharmacological profile of non-peptide neurotensin antagonistsD Gully, F Jeanjean, M Poncelet, et al.
Life Sciences|January 1, 1996
Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensinD Gully, L Lespy, M Canton, et al.
Kidney International|August 1, 1996
Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059C Serradeil-Le Gal, D Raufaste, E Marty, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 29, 2001
Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidusB Pouzet, C Serradeil-Le Gal, N Bouby, et al.
Biochemical and Biophysical Research Communications|October 23, 1997
Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cellsS Ferry, B Chatel, R H Dodd, et al.
Biochemical and Biophysical Research Communications|February 28, 1994
Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranesC Serradeil-Le Gal, D Raufaste, E Marty, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatmentB Bourrié, E Bribes, M Esclangon, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 29, 2000
Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertensionF Lacheretz, A Barbier, C Serradeil-Le Gal, et al.
Thrombosis and Haemostasis|August 1, 1994
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1AP Savi, J Combalbert, C Gaich, et al.
Pageof 12